Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study

Journal of the American College of Cardiology

Volumn 59, Issue 9, 2012, Pages 854-855

  Flaker, Greg ^a   Ezekowitz, Michael ^a   Yusuf, Salim ^a   Wallentin, Lars ^a   Noack, Herbert ^a   Brueckmann, Martina ^a   Reilly, Paul ^a   Hohnloser, Stefan H ^a   Connolly, Stuart ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

BLEEDING; CARDIOVERSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; STROKE; TREATMENT RESPONSE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TACHYCARDIA, PAROXYSMAL; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84857351821     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.10.896     Document Type: Letter

References (1)

1. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151